<DOC>
	<DOCNO>NCT02615847</DOCNO>
	<brief_summary>Symptomatic sickle cell disease worldwide frequent cause hereditary hemolytic anemia recurrent pain crisis . Hemolysis , vaso- occlusive pain crisis hallmarks disease causative important socio-economic burden worldwide , especially Africa . Aside allogenic stem cell transplantation , rarely available expensive , present curative treatment patient sickle cell disease ( SCD ) . The current standard care include treatment hydroxycarbamide symptomatic care transfusion , antibiotic/analgesic treatment . This study aim study safety tolerability Memantin patient sickle cell disease .</brief_summary>
	<brief_title>Clinical Trial Study Safety Tolerability Memantin MephaÂ® Sickle Cell Disease Patients</brief_title>
	<detailed_description>During study participant ask medical occurrence ( AEs ) happen laboratory analysis ( haematology , coagulation , chemistry ) urine sample take . In addition visit physical examination measurement vital sign perform . In addition number hospital day emergency consultation , impact work ability ( number day inability work , change iv % ) , amount type analgesic medication , amount RBC transfusion , number day antibiotic prescribed haematology ( local external laboratory ) chemistry laboratory parameter assess . For impact work social life questionnaire quality life fill monthly patient . At screen end study SCD specific assessment perform , include cardiologic examination ( ECG , ECHO ) , abdominal sonography , ophthalmological examination , lung function test neuroangiologic examination .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Documented symptomatic sickle cell disease ( HbSS HbS/beta thalassemia ) Age 18 year older Able willing provide write informed consent comply study protocol procedure Willing use two effective method contraception study treatment 6 month stop study treatment . Effective contraception method consider oral , injectable , implantative contraceptive intrauterine contraceptive device combine use condom . History transfusion last three month Screening Patients active bacterial , viral fungal infection require systemic treatment Patients know infection human immunodeficiency virus ( HIV ) human T cell leukaemia virus 1 ( HTLV1 ) Inadequate renal function : creatinine clearance &lt; 30ml/min Inadequate liver function : NCICTC Grade 3 liver function test ( AST , ALT &gt; 5x upper limit normal ( ULN ) ) History malignancy Women pregnant breast feed Previous know mental disorder know family history psychiatric disease Known epileptic disease The receipt investigational product within 30 day prior trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>